INCB123667 is an orally bioavailable small-molecule inhibitor of cyclin-dependent kinase 2 (CDK2). It binds and inhibits CDK2 activity, blocking retinoblastoma protein phosphorylation and the G1/S transition, which leads to cell cycle arrest. It is being studied in ovarian cancer.
Summary written with AI from the sources listed at the end of this page.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.